Related Experiment Videos
CPT-11: a novel antitumor drug
1Institut Gustave-Roussy, Villejuif, France.
Japanese Journal of Cancer Research : Gann
|August 1, 1994
Summary
No abstract available in PubMed .
Related Concept Videos
Articles linked to this work by shared authors, journal, and citation graph.
Immune-related adverse events with immune checkpoint blockade: a comprehensive review.
European journal of cancer (Oxford, England : 1990)·2016
Sequential research-related biopsies in phase I trials: acceptance, feasibility and safety.
Annals of oncology : official journal of the European Society for Medical Oncology·2011
A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours.
British journal of cancer·2010
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
European journal of cancer (Oxford, England : 1990)·2009
Procarbazine in haematology: an old drug with a new life?
European journal of cancer (Oxford, England : 1990)·2004
Beta-hydroxyisovalerylshikonin is a novel and potent inhibitor of protein tyrosine kinases.
Japanese journal of cancer research : Gann·2003
Calponin h1 suppresses tumor growth of Src-induced transformed 3Y1 cells in association with a decrease in angiogenesis.
Japanese journal of cancer research : Gann·2003
Dendritic cell appearance and differentiation during early and late stages of rat stomach carcinogenesis.
Japanese journal of cancer research : Gann·2003
Natural antigenic peptides from squamous cell carcinoma recognized by autologous HLA-DR8-restricted CD4+ T cells.
Japanese journal of cancer research : Gann·2003
Molecular cytogenetic characterization of drug-resistant leukemia cell lines by comparative genomic hybridization and fluorescence in situ hybridization.
Japanese journal of cancer research : Gann·2003
Targeting CXCR2 in Nociceptive Sensory Neurons Offers Novel Therapeutic Potentials for Postoperative Pain.
Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2026
Letter to "NR1D2 Knockdown Alleviates Myocardial Infarction Through Nrf2 Signaling Pathway Activation".
Cardiovascular drugs and therapy·2026
ERK1/2 Inhibitor Ulixertinib in Pan-cancer Patients with BRAF Fusions or Non-V600E/K Mutations: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1L.
Clinical cancer research : an official journal of the American Association for Cancer Research·2026